Journal Article Summary

The article investigates how the CYP3A5 genotype affects the way atorvastatin, a commonly prescribed cholesterol-lowering medication, is processed in the body, particularly when taken with clarithromycin, an antibiotic that can inhibit the metabolism of atorvastatin. Understanding this interaction is important because atorvastatin can cause muscle-related side effects in some patients, and clarithromycin may increase the risk of these side effects by affecting how atorvastatin is metabolized. The study aims to clarify whether genetic differences in CYP3A5, an enzyme involved in drug metabolism, significantly influence atorvastatin's effectiveness and safety.

In this study, 23 healthy volunteers participated, with their CYP3A5 genotypes classified as either expressors (those with the CYP3A5*1 allele) or nonexpressors (those without it). Participants received atorvastatin alone and then atorvastatin alongside clarithromycin in a controlled setting. The findings revealed that while there was a slight difference in the levels of atorvastatin lactone between the two genotype groups when atorvastatin was taken alone, these differences were not significant when clarithromycin was also administered. Overall, the CYP3A5 genotype appeared to have minimal impact on how atorvastatin is metabolized and its interaction with clarithromycin.

The study has some limitations, including a small sample size and the lack of evaluation of other genetic factors that could influence atorvastatin metabolism. Additionally, the study did not assess the potential effects of other relevant genetic variations beyond CYP3A5 and SLCO1B1. Patients should discuss their genetic background and any medications they are taking with their healthcare provider, especially if they are prescribed atorvastatin and clarithromycin together, to ensure safe and effective treatment.

Medication Safety Note

This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.

Article Cited

  1. Shin Jaekyu, Pauly Daniel F., Pacanowski Michael A., Langaee Taimour, Frye Reginald F., Johnson Julie A.. Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin. Pharmacotherapy 2011. DOI: 10.1592/phco.31.10.942. PMID: 21950641. PMCID: PMC3712822.

Featured Pill Pals Product

Pill Pals® is THE Express Pharmacy. Our Nationwide Pharmacy Network was created with the mission of helping you make SENSE of your meds™. As a Pharmacy Benefits Management organization, Pill Pals® gives patients the best cash prices on all meds. Pill Pals® is part of The Health Pals® Company (Health Pals®, Med Pals®, Skin Pals® etc), a vertically integrated Healthcare System that provides cost effective Medical and Pharmacy services to Employers, Patients, and more. For more information, please email [email protected]